SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence

Cell Death and Differentiation

Volumn 18, Issue 2, 2011, Pages 304-314

  Wang, X D ^a   Lapi, E ^a   Sullivan, A ^a,d   Ratnayaka, I ^a   Goldin, R ^b   Hay, R ^c   Lu, X ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ASPP2; cyclin D1; Ras; senescence; SUMO

Indexed keywords

APOPTOSIS STIMULATING PROTEIN OF P53; CYCLIN D1; LYSINE; PROTEIN P19; PROTEIN P21; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; SUMO PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; EMBRYO; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SENESCENCE; SUMOYLATION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; CELL AGING; CELL NUCLEUS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FIBROBLASTS; MICE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; RAS PROTEINS; RETINOBLASTOMA PROTEIN; SUMO-1 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 78651312057     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.101     Document Type: Article

References (39)

1. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998;52: 1-15.
2. Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Yamamoto M, Inoue M et al. Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000;16: 261-266.
3. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes &Dev 1993;7: 1559-1571.
4. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14: 1669-1679.
5. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes &Dev 1998;12: 3499-3511.
6. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes &Dev 2000;14: 3102-3114.
7. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006;25: 998-1007.
8. Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 2008;27: 1231-1242.
9. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004;73: 355-382.
10. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 2000;275: 6252-6258.
11. Matic I, van Hagen M, Schimmel J, Macek B, Ogg SC, Tatham MH et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol Cell Proteomics 2008;7: 132-144.
12. Anckar J, Sistonen L. SUMO: getting it on. Biochem Soc Trans 2007;35 (Pt 6): 1409-1413.
13. Lloyd AC. Ras versus cyclin-dependent kinase inhibitors. Curr Opin Genet Dev 1998;8: 43-48.
14. Pantoja C, Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 1999;18: 4974-4982.
15. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88: 593-602.
16. Sebastian T, Malik R, Thomas S, Sage J, Johnson PF. C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. EMBO J 2005;24: 3301-3312.
17. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 2009;11: 1451-1457.
18. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001;8: 781-794.
19. Vives V, Su J, Zhong S, Ratnayaka I, Slee E, Goldin R et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes &Dev 2006;20: 1262-1267.
20. Kampa KM, Acoba JD, Chen D, Gay J, Lee H, Beemer K et al. Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci USA 2009;106: 4390-4395.
21. Liu ZJ, Lu X, Zhang Y, Zhong S, Gu SZ, Zhang XB et al. Downregulated mRNA expression of ASPP and the hypermethylation of the 50-untranslated region in cancer cell lines retaining wild-type p53. FEBS Letters 2005;579: 1587-1590.
22. Lossos IS, Natkunam Y, Levy R, Lopez CD. Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma 2002;43: 2309-2317.
23. Yang JP, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T. NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 1999;18: 5177-5186.
24. Naumovski L, Cleary ML. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol Cell Biol 1996;16: 3884-3892.
25. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, Barford D. Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. EMBO J 1997;16: 1876-1887.
26. Espanel X, Sudol M. YES-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 2001;276: 14514-14523.
27. Nakagawa H, Koyama K, Murata Y, Morito M, Akiyama T, Nakamura Y. APCL, a central nervous system-specific homologue of adenomatous polyposis coli tumor suppressor, binds to p53-binding protein 2 and translocates it to the perinucleus. Cancer Res 2000;60: 101-105.
28. Chen Y, Liu W, McPhie DL, Hassinger L, Neve RL. APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J Cell Biol 2003;163: 27-33.
29. Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 2008;14: 68-78.
30. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PloS One 2006;1: e128.
31. Xue Y, Zhou F, Fu C, Xu Y, Yao X. SUMOsp: a web server for SUMOylation site prediction. Nucleic Acids Res 2006;34 (Web Server issue): W254-W257.
32. Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell 2006;24: 355-366.
33. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev 2003;3: 11-22.
34. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997;11: 957-972.
35. Benzeno S, Diehl JA. C-terminal sequences direct cyclin D1-CRM1 binding. J Biol Chem 2004;279: 56061-56066.
36. Rodriguez MS, Dargemont C, Hay RT. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 2001;276: 12654-12659.
37. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57: 353-361.
38. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002;22: 3389-3403.
39. Slee EA, Gillotin S, Bergamaschi D, Royer C, Llanos S, Ali S et al. The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 2004;23: 9007-9016.